98%
921
2 minutes
20
Obesity is a common disease of developing countries, including Pakistan. Obesity is a risk factor for many diseases which can be life threatening or making the person unable to perform daily routine work. In the current study, clinical trials were designed to evaluate the effects of medical intervention by comparing the effects of placebo control drug "Plasicure" with the herbal medicinal formulation "Obesecure". The test drug formulation was designed on the basis of the screening study for Leptogenic drugs. To evaluate the safety of the test drug, the toxicity index and the safety profile of test formulation was assessed on animal models. The drug was found safe for further clinical study. Randomized Controlled Clinical Trials were conducted. The statistical analysis was carried out by the application of Two-Way Repeated Analysis of Variance test. The clinical findings of randomized controlled trial revealed that the test drug was Leptogenic and effective in weight reduction as compared to control drug Plasicure therapy as the p-value deduced was 0.001 in leptin level and 0.000 in case of BMI after the conduction of Two-Way Repeated Analysis of Variance test. Hence it is concluded that obscure therapy is more significant than control drug Plasicure therapy in the management and treatment of obesity.
Download full-text PDF |
Source |
---|
Int J Epidemiol
August 2025
Department of Biostatistics and Informatics, University of Colorado, Aurora, CO, United States.
Background: Existing longitudinal cohort study data and associated biospecimen libraries provide abundant opportunities to efficiently examine new hypotheses through retrospective specimen testing. Outcome-dependent sampling (ODS) methods offer a powerful alternative to random sampling when testing all available specimens is not feasible or biospecimen preservation is desired. For repeated binary outcomes, a common ODS approach is to extend the case-control framework to the longitudinal setting.
View Article and Find Full Text PDFN Engl J Med
September 2025
Rwanda Biomedical Center, Kigali.
Background: On September 27, 2024, Rwanda reported an outbreak of Marburg virus disease (MVD), after a cluster of cases of viral hemorrhagic fever was detected at two urban hospitals.
Methods: We report key aspects of the epidemiology, clinical manifestations, and treatment of MVD during this outbreak, as well as the overall response to the outbreak. We performed a retrospective epidemiologic and clinical analysis of data compiled across all pillars of the outbreak response and a case-series analysis to characterize clinical features, disease progression, and outcomes among patients who received supportive care and investigational therapeutic agents.
Pol Merkur Lekarski
September 2025
LLC "ECOFARM", KYIV, UKRAINE.
Objective: Aim: To consider the specific activity of drops and suppositories of PROTEFLAZID® at the stage of preclinical study, to assess the effectiveness and safety of use in clinical practice in papillomavirus-associated diseases of the female reproductive system..
Patients And Methods: Materials and Methods: Analysis of scientific publications on the treatment of palilomavirus infection with PROTEFLAZID® in women over the past decade.
Pol Merkur Lekarski
September 2025
I. HORBACHEVSKY TERNOPIL NATIONAL MEDICAL UNIVERSITY, TERNOPIL, UKRAINE.
Objective: Aim: To evaluate the state of oxidation processes and morphological changes in the heart of rats with chronic hypodynamia during the development of epinephrine heart damage (EHD)..
Patients And Methods: Materials and Methods: The study was performed on 144 white male Wistar rats.
J Bras Pneumol
September 2025
. Programa de Pós-Graduação em Ciências Médicas, Universidade Federal de Santa Catarina, Florianópolis (SC) Brasil.
Objective: To describe the impact of severe asthma in a real-life cohort in Brazil, reporting on baseline clinical characteristics, access to treatment, and clinical remission under treatment with biologics.
Methods: Severe asthma patients > 6 years of age were recruited from 23 centers in Brazil. Data on clinical characteristics, lung function, biomarkers, prescribed therapies, and clinical remission under treatment were collected at the baseline visit.